Hormone Health · Peptide Guide
Before committing to exogenous testosterone, it is worth understanding what other options exist for men with low testosterone, and which options actually work. The framing of “TRT vs…
This guide separates the evidence-backed from the ineffective, introduces the pharmaceutical approaches that genuinely compete with TRT in appropriate patients, and gives a framework for thinking through which path makes sense for whom.
TRT: Replacement
External testosterone is delivered into the body, raises blood levels directly, and in the process, signals the brain that testosterone is adequate. This suppresses the hypothalamic-pituitary-gonadal (HPG) axis, GnRH and LH production falls, the testes stop producing their own testosterone, sperm production is suppressed, and testicular size reduces. TRT works regardless of where the problem is in the axis, because it bypasses it entirely.
Natural Optimisation: Stimulation
The HPG axis is stimulated, either through lifestyle changes that remove suppressors of the axis (stress, obesity, poor sleep) or through pharmaceutical signals that tell the pituitary or testes to produce more of their own testosterone. The axis remains active. LH and FSH remain elevated. Spermatogenesis continues. Testicular function and size are preserved. This only works if the relevant part of the axis is functional.
Hypothalamus
Releases GnRH
→
Pituitary
Releases LH + FSH
→
Testes
Produce T + Sperm
→
Testosterone
Feeds back to suppress GnRH + LH
Primary hypogonadism, the testes fail to produce adequate testosterone despite normal or elevated LH and FSH. The pituitary is already signalling maximally; the problem is downstream at the testes. SERMs and lifestyle changes cannot fix this. TRT is the appropriate treatment.
Secondary (functional) hypogonadism, the pituitary is not signalling adequately, often because obesity, sleep apnoea, chronic stress, or medications suppress GnRH. The testes are capable of producing testosterone if properly stimulated. This is where lifestyle optimisation and SERMs or hCG work best.
Before any pharmaceutical, whether TRT, clomiphene, or enclomiphene, the first clinical step for men with secondary or functional hypogonadism is addressing the lifestyle factors that suppress testosterone. For some men, this is sufficient to restore levels to normal without any medication.
High Impact
Weight Loss
Adipose tissue contains aromatase, the enzyme that converts testosterone to estrogen. Obesity is one of the most potent modifiable suppressors of testosterone. Significant weight loss in obese hypogonadal men consistently raises testosterone, often substantially. The TRAVERSE trial notably found that men with BMI ≥30 had testosterone that mirrored hypogonadism, before any hormonal cause was identified.
High Impact
Sleep Optimisation
Testosterone is predominantly produced during sleep. Even one night of sleep restricted to 5 hours reduces testosterone by 10–15% in healthy young men. Chronic sleep restriction creates a persistent deficit. More critically, obstructive sleep apnoea (OSA) is a major, and reversible, cause of low testosterone: CPAP treatment for OSA consistently raises testosterone without any hormone therapy.
High Impact
Resistance Training
Strength training acutely and chronically raises testosterone. Regular resistance training is one of the most consistently evidenced non-pharmacological testosterone-raising interventions in humans. Free testosterone rises particularly with compound movements and higher-intensity protocols. The benefit compounds with improved body composition over time.
High Impact
Stress Reduction
Chronic psychological stress chronically elevates cortisol, which directly suppresses GnRH secretion at the hypothalamus and reduces testosterone production at the testes. Men with chronically elevated cortisol from occupational stress, relationship stress, or anxiety disorders can have testosterone suppressed through this mechanism, and may respond dramatically to stress management without any pharmacological intervention.
Moderate Impact
Alcohol Reduction
Even moderate alcohol consumption (more than 2 drinks per day) impairs the HPG axis and reduces testosterone. Alcohol is directly toxic to Leydig cells (testicular testosterone producers) at higher doses. Reducing or eliminating alcohol is one of the more accessible lifestyle changes with documented testosterone impact.
If Deficient
Vitamin D & Zinc
Deficiencies in vitamin D and zinc impair testosterone synthesis. Supplementation raises testosterone in deficient men, but does not raise testosterone meaningfully in men who are already replete. Testing first and supplementing only if deficient is the evidence-based approach. This is the principle that separates vitamin D from marketing.
The Critical Distinction
Lifestyle optimisation works primarily for secondary or functional hypogonadism, where lifestyle factors are actively suppressing the axis. For men with primary hypogonadism (testicular failure), lifestyle optimisation can improve overall health and wellbeing significantly, but it will not restore testosterone to normal levels because the problem is structural, not functional.
10 RCTs analysed
819 patients
+273.76 ng/dL vs placebo
No significant difference vs T gel
Spermatogenesis preserved
A 2025 systematic review and meta-analysis from the Federal University of Santa Catarina (10 RCTs, 819 patients, published in Archives of Endocrinology and Metabolism) confirmed that SERMs, clomiphene and enclomiphene, raise testosterone to levels comparable to testosterone gel in men with secondary hypogonadism, while preserving sperm production that TRT suppresses. Both LH and FSH rose significantly with SERMs vs placebo; they fell significantly with T gel. The authors emphasised: “SERMs restore testosterone levels physiologically by stimulating the body’s own hormonal axis and avoid the risks associated with exogenous replacement.”[1]
Selective Estrogen Receptor Modulator, established off-label use in men
How it works
Blocks estrogen receptors in hypothalamus + pituitary → body “thinks” estrogen is low → increases GnRH, LH, FSH → testes produce more testosterone
Administration
Oral tablet, 25–50mg daily or every other day
Evidence
AUA guidelines recommend for men with hypogonadism + fertility goals. Multiple RCTs. Used off-label (FDA approved for female infertility).
Fertility impact
Preserves and often improves spermatogenesis, the key advantage over TRT
The limitation: Clomiphene contains two isomers, zuclomiphene (estrogenic, longer half-life) and enclomiphene (antiestrogenic). The zuclomiphene component can cause visual disturbances (rarely), mood changes, and mild estrogenic side effects including breast tenderness. It also slightly elevates estradiol, which is generally acceptable but warrants monitoring. For most men with secondary hypogonadism and fertility goals, clomiphene is the most accessible first-line SERM, it has the longest track record and is widely available at pharmacies.
Purified antiestrogenic isomer, improved side effect profile vs clomiphene
What it is
The pure trans-isomer of clomiphene, the antiestrogenic component without the estrogenic zuclomiphene
Administration
Oral tablet, available through compounding pharmacies; not FDA-approved as standalone
Evidence (2024, Baylor)
Median testosterone increase of 166 ng/dL, lower estradiol rise vs clomiphene, fewer documented adverse events
Fertility impact
Preserves spermatogenesis; studies show sperm concentration maintained or improved vs TRT-induced decline
The advantage: By removing the zuclomiphene component, enclomiphene delivers the testosterone-stimulating benefit of SERM therapy with a cleaner side effect profile. It produces lower estradiol elevation than clomiphene, which matters for men sensitive to estrogen-related effects. The 2024 Baylor College of Medicine study (Saffati et al., Translational Andrology and Urology) found fewer documented adverse events with enclomiphene compared to clomiphene in men who had been on both sequentially.[2]
The limitation: Enclomiphene is not FDA-approved as a standalone drug and is only available through compounding pharmacies. This limits insurance coverage and may affect accessibility and quality control.
LH analogue, stimulates the testes directly to produce testosterone and maintain function
How it works
Mimics LH, directly stimulates Leydig cells in the testes to produce testosterone. Bypasses the pituitary level; acts further downstream in the HPG axis.
Administration
Subcutaneous injection (self-administered), typically 500–1000 IU 2–3× per week
Evidence
Study (n=282): hCG raised testosterone by 245 ng/dL; clomiphene by 304 ng/dL; combination by 305 ng/dL. European Urology guidelines recommend for secondary hypogonadism + fertility.
Key uses
Standalone for secondary hypogonadism. Combined with TRT to prevent testicular atrophy and preserve some spermatogenesis during testosterone therapy.
The advantage over SERMs: hCG works more directly and may produce faster results. It is useful for men who cannot tolerate or respond to oral SERMs, and it is the primary adjunct used during TRT to maintain testicular function in men who want to minimise testicular atrophy or attempt to preserve some fertility while on testosterone.
The limitation: Injection-based administration is a barrier for some men. hCG can also elevate estradiol significantly (it stimulates the testes to produce estradiol alongside testosterone), occasionally requiring aromatase inhibitor management. Compounding hCG availability has also been restricted by FDA reclassification, brand name Pregnyl (hospital-grade hCG) remains accessible.
| Factor | TRT | Clomiphene / Enclomiphene | hCG |
|---|---|---|---|
| Testosterone increase | Most reliable; dose-adjustable to target range | +273 ng/dL avg (SERMs); comparable to T gel in RCTs | +245 ng/dL (hCG alone); higher in combination |
| Spermatogenesis | Suppressed, TRT is effectively a contraceptive | Preserved and often improved, key advantage | Maintained, hCG maintains testicular function |
| Works in primary hypogonadism? | Yes, bypasses the axis | No, requires a functional pituitary + testes | Partially, stimulates testes directly if some Leydig cell function remains |
| Testicular size | Reduces with time | Maintained or increased | Maintained, hCG prevents atrophy |
| Administration | Daily gel / weekly injection / 3–6 month pellets | Daily oral tablet, most convenient | Subcutaneous injection 2–3× per week |
| Erythrocytosis risk | Yes, elevated haematocrit is the most common adverse effect | No, preserved HPG axis, no polycythaemia risk | Lower risk than TRT |
| FDA approval | Approved for hypogonadism from specific causes | Clomiphene: off-label (approved for female infertility). Enclomiphene: compounding only, not FDA-approved. | Brand Pregnyl: approved; compounding hCG: restricted |
| Long-term data | Extensive, decades of use, TRAVERSE 27-month RCT | Clomiphene: years of off-label use data; long-term safety still accumulating | Decades of use in reproductive medicine; hypogonadism-specific long-term data more limited |
Our free quiz helps you think through your situation before speaking with a clinician.